CLINICAL IMMUNOLOGY
Salivary interleukin 6, interleukin 8, interleukin 17A, and tumour necrosis factor α levels in patients with periodontitis and rheumatoid arthritis
1
Department of Periodontology and Oral Mucosa Diseases, Medical University of Warsaw, Warsaw, Poland
2
Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
3
Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
4
Department of Social Nursing, Medical University of Warsaw, Warsaw, Poland
5
Department of Immunopathology of Infectious and Parasitic Diseases, Medical University of Warsaw, Warsaw, Poland
Submission date: 2019-03-11
Acceptance date: 2019-03-30
Publication date: 2019-09-30
Cent Eur J Immunol 2019;44(3):269-276
KEYWORDS
periodontitisrheumatoid arthritissalivary diagnosticsinterleukin 6interleukin 8interleukin 17Atumour necrosis factor α
ABSTRACT
Introduction:
Rheumatoid arthritis (RA) and periodontitis share risk factors and inflammatory pathways that could be related to cytokines, such as interleukin (IL)-6, IL-8, IL-17A, and tumour necrosis factor-α (TNF-α). The aim of this study was to compare periodontal status and salivary levels of selected cytokines between patients diagnosed with RA and periodontitis. RA patients were assessed for the potential influence of anti-rheumatic therapy.
Material and methods:
One hundred and six patients were enrolled in a cross-sectional study. Medical assessment and periodontal examination were performed in 35 patients with chronic periodontitis, in 35 patients with RA and chronic periodontitis, and in 36 controls. Unstimulated whole saliva samples were analysed for IL-6, IL-8, IL-17A, and TNF-α.
Results:
Significant differences in biomarkers and periodontal parameters were found among groups. Study groups exhibited higher mean pocket depth (PD), number of PD > 4 mm, and mean clinical attachment loss, when compared with controls. The RA group had lower bleeding on probing index and PD, but higher values of plaque indices than the periodontitis group. Concentration of evaluated cytokines were higher in the RA and periodontitis groups, compared with controls. The periodontitis group showed also higher levels of IL-6, IL-17A, and TNF-α in comparison to RA. RA patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and glucocorticosteroids.
Conclusions:
Salivary levels of IL-6, IL-8, IL-17A, and TNF-α can be affected by periodontitis, RA, and presumably DMARDs. DMARD therapy appears to reduce destructive and inflammatory processes in periodontal tissues because lower values of PD, BOP, and salivary levels of IL-6, IL-17A, and TNF-α were found in RA.
Rheumatoid arthritis (RA) and periodontitis share risk factors and inflammatory pathways that could be related to cytokines, such as interleukin (IL)-6, IL-8, IL-17A, and tumour necrosis factor-α (TNF-α). The aim of this study was to compare periodontal status and salivary levels of selected cytokines between patients diagnosed with RA and periodontitis. RA patients were assessed for the potential influence of anti-rheumatic therapy.
Material and methods:
One hundred and six patients were enrolled in a cross-sectional study. Medical assessment and periodontal examination were performed in 35 patients with chronic periodontitis, in 35 patients with RA and chronic periodontitis, and in 36 controls. Unstimulated whole saliva samples were analysed for IL-6, IL-8, IL-17A, and TNF-α.
Results:
Significant differences in biomarkers and periodontal parameters were found among groups. Study groups exhibited higher mean pocket depth (PD), number of PD > 4 mm, and mean clinical attachment loss, when compared with controls. The RA group had lower bleeding on probing index and PD, but higher values of plaque indices than the periodontitis group. Concentration of evaluated cytokines were higher in the RA and periodontitis groups, compared with controls. The periodontitis group showed also higher levels of IL-6, IL-17A, and TNF-α in comparison to RA. RA patients were treated with disease-modifying anti-rheumatic drugs (DMARDs) and glucocorticosteroids.
Conclusions:
Salivary levels of IL-6, IL-8, IL-17A, and TNF-α can be affected by periodontitis, RA, and presumably DMARDs. DMARD therapy appears to reduce destructive and inflammatory processes in periodontal tissues because lower values of PD, BOP, and salivary levels of IL-6, IL-17A, and TNF-α were found in RA.
REFERENCES (75)
1.
Konopka T, Dembowska E, Pietruska M, et al. (2015): Periodontal status and selected parameters of oral condition of Poles aged 65 to 74 years. Przegl Epidemiol 69: 537-542.
2.
Kuo LC, Polson AM, Kang T (2008): Associations between periodontal diseases and systemic diseases: a review of the inter-relationships and interactions with diabetes, respiratory diseases, cardiovascular diseases and osteoporosis. Public Health 122: 417-433.
3.
Ayravainen L, Leirisalo-Repo M, Kuuliala A, et al. (2017): Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population. BMJ Open 7: e011916.
4.
Choi IA, Kim JH, Kim YM, et al. (2016): Periodontitis is associated with rheumatoid arthritis: a study with longstanding rheumatoid arthritis patients in Korea. Korean J Intern Med 31: 977-986.
5.
Grasso MA, Comer AC, DiRenzo DD, et al. (2016): Using Big Data to Evaluate the Association between Periodontal Disease and Rheumatoid Arthritis. AMIA Annu Symp Proc 2015: 589-593.
6.
Chou YY, Lai KL, Chen DY, et al. (2015): Rheumatoid Arthritis Risk Associated with Periodontitis Exposure: A Nationwide, Population-Based Cohort Study. PLoS One 10: e0139693.
7.
Schmickler J, Rupprecht A, Patschan S, et al. (2017): Cross-Sectional Evaluation of Periodontal Status and Microbiologic and Rheumatoid Parameters in a Large Cohort of Patients With Rheumatoid Arthritis. J Periodontol 88: 368-379.
8.
Khantisopon N, Louthrenoo W, Kasitanon N, et al. (2014): Periodontal disease in Thai patients with rheumatoid arthritis. Int J Rheum Dis 17: 511-518.
9.
Tang Q, Fu H, Qin B, et al. (2017): A Possible Link Between Rheumatoid Arthritis and Periodontitis: A Systematic Review and Meta-analysis. Int J Periodontics Restorative Dent 37: 79-86.
10.
Fuggle NR, Smith TO, Kaul A, et al. (2016): Hand to Mouth: A Systematic Review and Meta-Analysis of the Association between Rheumatoid Arthritis and Periodontitis. Front Immunol 7: 80.
11.
Stolt P, Bengtsson C, Nordmark B, et al. (2003): Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 62: 835-841.
12.
Tomar SL, Asma S (2000): Smoking-attributable periodontitis in the United States: findings from NHANES III. National Health and Nutrition Examination Survey. J Periodontol 71: 743-751.
13.
Bonfil JJ, Dillier FL, Mercier P, et al. (1999): A “case control” study on the role of HLA DR4 in severe periodontitis and rapidly progressive periodontitis. Identification of types and subtypes using molecular biology (PCR.SSO). J Clin Periodontol 26: 77-84.
14.
Gregersen PK, Silver J, Winchester RJ (1987): The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 30: 1205-1213.
15.
de Almeida DE, Ling S, Holoshitz J (2011): New insights into the functional role of the rheumatoid arthritis shared epitope. FEBS Lett 585: 3619-3626.
16.
Ortiz P, Bissada NF, Palomo L, et al. (2009): Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol 80: 535-540.
17.
Al-Katma MK, Bissada NF, Bordeaux JM, et al. (2007): Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol 13: 134-137.
18.
Khare N, Vanza B, Sagar D, et al. (2016): Nonsurgical Periodontal Therapy decreases the Severity of Rheumatoid Arthritis: A Case-control Study. J Contemp Dent Pract 17: 484-488.
19.
Erciyas K, Sezer U, Ustun K, et al. (2013): Effects of periodontal therapy on disease activity and systemic inflammation in rheumatoid arthritis patients. Oral Dis 19: 394-400.
20.
Andrade R, Espinoza M, Gomez EM, et al. (2012): Intra- and inter-examiner reproducibility of manual probing depth. Braz Oral Res 26: 57-63.
21.
Lamster IB, Ahlo JK (2007): Analysis of gingival crevicular fluid as applied to the diagnosis of oral and systemic diseases. Ann N Y Acad Sci 1098: 216-229.
22.
Kim JJ, Kim CJ, Camargo PM (2013): Salivary biomarkers in the diagnosis of periodontal diseases. J Calif Dent Assoc 41: 119-124.
23.
Giannobile WV, Beikler T, Kinney JS, et al. (2009): Saliva as a diagnostic tool for periodontal disease: current state and future directions. Periodontol 2000 50: 52-64.
24.
Christodoulides N, Floriano PN, Miller CS, et al. (2007): Lab-on-a-chip methods for point-of-care measurements of salivary biomarkers of periodontitis. Ann N Y Acad Sci 1098: 411-428.
25.
Mirrielees J, Crofford LJ, Lin Y, et al. (2010): Rheumatoid arthritis and salivary biomarkers of periodontal disease. J Clin Periodontol 37: 1068-1074.
26.
Gamel EB, Hashim NT, Satti A, Gismalla BG (2017): Salivary TNF-αlpha levels in groups of subjects with rheumatoid arthritis and chronic periodontitis. BMC Res Notes 10: 34.
27.
Rathnayake N, Akerman S, Klinge B, et al. (2013): Salivary biomarkers of oral health: a cross-sectional study. J Clin Periodontol 40: 140-147.
28.
Madhok R, Crilly A, Watson J, Capell HA (1993): Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 52: 232-234.
29.
Georganas C, Liu H, Perlman H, et al. (2000): Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 165: 7199-7206.
30.
Suzuki M, Hashizume M, Yoshida H, Mihara M (2010): Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30: 309-315.
31.
Hirano T, Akira S, Taga T, Kishimoto T (1990): Biological and clinical aspects of interleukin 6. Immunol Today 11: 443-449.
32.
Finoti LS, Nepomuceno R, Pigossi SC, et al. (2017): Association between interleukin-8 levels and chronic periodontal disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 96: e6932.
33.
Shimada Y, Komatsu Y, Ikezawa-Suzuki I, et al. (2010): The effect of periodontal treatment on serum leptin, interleukin-6, and C-reactive protein. J Periodontol 81: 1118-1123.
34.
Lagdive SS, Marawar PP, Byakod G, Lagdive SB (2013): Evaluation and comparison of interleukin-8 (IL-8) level in gingival crevicular fluid in health and severity of periodontal disease: a clinico-biochemical study. Indian J Dent Res 24: 188-192.
35.
Husby G, Williams RC (1988): Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1: 363-371.
36.
Jiang ZL, Cui YQ, Gao R, et al. (2013): Study of TNF-αlpha, IL-1beta and LPS levels in the gingival crevicular fluid of a rat model of diabetes mellitus and periodontitis. Dis Markers 34: 295-304.
37.
Feldmann M (2002): Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2: 364-371.
38.
Gumus P, Nizam N, Lappin DF, Buduneli N (2014): Saliva and serum levels of B-cell activating factors and tumor necrosis factor-alpha in patients with periodontitis. J Periodontol 85: 270-280.
39.
Teles RP, Likhari V, Socransky SS, Haffajee AD (2009): Salivary cytokine levels in subjects with chronic periodontitis and in periodontally healthy individuals: a cross-sectional study. J Periodontal Res 44: 411-417.
40.
Lubberts E, Joosten LA, Oppers B, et al. (2001): IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 167: 1004-1013.
41.
Azizi G, Jadidi-Niaragh F, Mirshafiey A (2013): Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. Int J Rheum Dis 16: 243-253.
42.
Cheng WC, Hughes FJ, Taams LS (2014): The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol 4: 541-549.
43.
Armitage GC (1999): Development of a classification system for periodontal diseases and conditions. Ann Periodontol 4: 1-6.
44.
Aletaha D, Neogi T, Silman AJ, et al. (2010): 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581.
45.
Caton J, Armitage G, Berglundh T, et al. (2018): A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Clin Periodontol 45: S1-S8.
46.
Prevoo ML, van ‘t Hof MA, Kuper HH, et al. (1995): Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
47.
Ainamo J, Bay I (1975): Problems and proposals for recording gingivitis and plaque. Int Dent J 25: 229-235.
48.
O’Leary TJ, Drake RB, Naylor JE (1972): The plaque control record. J Periodontol 43: 38.
49.
Lange DE, Plagmann HC, Eenboom A, Promesberger A (1977): Clinical methods for the objective evaluation of oral hygiene. Dtsch Zahnarztl Z 32: 44-47.
51.
Silvestre-Rangil J, Bagán L, Silvestre FJ, et al. (2017): Periodontal, salivary and IL-6 status in rheumatoid arthritis patients. A cross-sectional study. Med Oral Patol Oral Cir Bucal 22: e595-e600.
52.
Bozkurt FY, Berker E, Akkus S, Bulut S (2000): Relationship between interleukin-6 levels in gingival crevicular fluid and periodontal status in patients with rheumatoid arthritis and adult periodontitis. J Periodontol 71: 1756-1760.
53.
Cetinkaya B, Guzeldemir E, Ogus E, Bulut S (2013): Proinflammatory and anti-inflammatory cytokines in gingival crevicular fluid and serum of patients with rheumatoid arthritis and patients with chronic periodontitis. J Periodontol 84: 84-93.
54.
Ziebolz D, Rupprecht A, Schmickler J, et al. (2018): Association of different immunosuppressive medications with periodontal condition in patients with rheumatoid arthritis: Results from a cross-sectional study. J Periodontol 89: 1310-1317.
55.
Seitz M (1999): Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 11: 226-232.
56.
Aggarwal A, Misra R (2003): Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 23: 134-137.
57.
Gao IK, Leins C, Bohlen H, et al. (1998): Inhibition of interleukin-8 synthesis by intraarticular methotrexate therapy in patients with rheumatoid arthritis. Z Rheumatol 57: 95-100.
58.
Li Y, Jiang L, Zhang S, et al. (2012): Methotrexate attenuates the Th17/IL-17 levels in peripheral blood mononuclear cells from healthy individuals and RA patients. Rheumatol Int 32: 2415-2422.
59.
Gerards AH, de Lathouder S, de Groot ER, et al. (2003): Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42: 1189-1196.
60.
Dessein PH, Joffe BI (2006): Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 24: 161-167.
61.
Zhu M, Xu Q, Li XL, et al. (2014): Modulating effects of leflunomide on the balance of Th17/Treg cells in collageninduced arthritis DBA/1 mice. Cent Eur J Immunol 39: 152-158.
62.
Li WD, Ran GX, Teng HL, Lin ZB (2002): Dynamic effects of leflunomide on IL-1, IL-6, and TNF-αlpha activity produced from peritoneal macrophages in adjuvant arthritis rats. Acta Pharmacol Sin 23: 752-756.
63.
Klimiuk PA, Kita J, Chwiecko J, Sierakowski S (2009): The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. Clin Rheumatol 28: 17-21.
64.
Rodenburg RJ, Ganga A, van Lent PL, et al. (2000): The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis. Arthritis Rheum 43: 1941-1950.
65.
Lodowska J, Gruchlik A, Wolny D, et al. (2015): The effect of sulfasalazine and 5-aminosalicylic acid on the secretion of interleukin 8 by human colon myofibroblast. Acta Pol Pharm 72: 917-921.
66.
Kyburz D, Brentano F, Gay S (2006): Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2: 458-459.
67.
Silva JC, Mariz HA, Rocha LF, et al. (2013): Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics (Sao Paulo) 68: 766-771.
68.
Dasgupta B, Corkill M, Kirkham B, et al. (1992): Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 19: 22-25.
69.
Kobayashi T, Murasawa A, Komatsu Y, et al. (2010): Serum cytokine and periodontal profiles in relation to disease activity of rheumatoid arthritis in Japanese adults. J Periodontol 81: 650-657.
70.
van Vollenhoven RF (2009): Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med 7: 12.
71.
Dineshkumar T, Ashwini BK, Rameshkumar A, et al. (2016): Salivary and Serum Interleukin-6 Levels in Oral Premalignant Disorders and Squamous Cell Carcinoma: Diagnostic Value and Clinicopathologic Correlations. Asian Pac J Cancer Prev 17: 4899-4906.
72.
St John MA, Li Y, Zhou X, et al. (2004): Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 130: 929-935.
73.
Wu M, Chen SW, Su WL, et al. (2016): Sex Hormones Enhance Gingival Inflammation without Affecting IL-1beta and TNF-αlpha in Periodontally Healthy Women during Pregnancy. Mediators Inflamm 2016: 4897890.
74.
Khan A (2012): Detection and quantitation of forty eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine. J Proteomics 75: 4802-4819.
75.
Szczeklik K, Owczarek D, Pytko-Polończyk J, et al. (2012): Proinflammatory cytokines in the saliva of patients with active and non-active Crohn’s disease. Pol Arch Med Wewn 122: 200-208.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
